Browse by ▼

Amgen, Inc.

  • This $28 Billion Hedge Fund Is Bullish

    By Meena Krishnamsetty - May 10, 2013 | Tickers: AMGN, DTE, KMB, MKC, VZ

    Looking at 13F filings is important because they reveal hedge funds' quarterly moves, and most crucially, their favorite equity investments. Institutional investors who exercise investment discretion of more than $100 million are required to report their positions in 13Fs several weeks after the end of each quarter. David Harding's Winton Capital Management is one of the funds that recently filed its 13F form with the Securities and Exchange Commission more »

  • Over 100% Asset Growth in This Minimum-Volatility ETF

    By Jeff Stouffer - April 30, 2013 | Tickers: AMGN, USMV, VZ

    When a new strategy hits the Street and it gains assets at a significant rate over a very short period of time, the ability of this new program to absorb the new money is quickly tested.

    A new exchange-traded fund named the iShares MSCI USA Minimum Volatility Index Fund (NYSEMKT: USMV) is an example of such a program. This ETF was brought to the marketplace on Oct. 18, 2011. In more »

  • A New Approach to Treating a Broken Heart

    By Seth Robey - April 29, 2013 | Tickers: AMGN, CYTK

    A failing heart is a lot like a glass Heinz Ketchup bottle.  Squeezing the bottle isn't very efficient, so you smack that strategically placed '57,' and still no condiment.  So you smack harder, and faster, until you've burned as many calories as you're about to consume.  Such is the natural response of a heart that can't adequately pump blood to the body - it beats harder, and more »

  • 2 Biotech Leaders Trade Lower: 1 to Buy and 1 to Sell

    By Brian Nichols - April 28, 2013 | Tickers: AMGN, LLY

    Biotechnology companies, specifically mid and large cap stocks, have led the market in performance for much of the last year. Two of the clear leaders, Eli Lilly (NYSE: LLY) and Amgen (NASDAQ: AMGN), both traded lower on Wednesday after reporting disappointing earnings. Investors must now consider if these two leaders are presenting opportunity or if these losses are the start of a larger fall.

    Eli Lilly

    In the last year more »

  • What Goes up Must Come Down

    By Shas Dey - April 16, 2013 | Tickers: AMGN, BIIB, CELG, GILD

    Biogen Idec (NASDAQ: BIIB) is one of those rare companies in the healthcare sector whose stock has relentlessly outperformed the broader market continuously for as long as one can remember. Year-to-date, it has gained almost 33% against less than 12% of S&P 500. Over five years, it has returned 202%. It has even outperformed the Healthcare SPDR ETF by almost 100%.

    On March 27, 2013, another dimension was added more »

  • Biotech Madness!

    By Greg Williamson - April 1, 2013 | Tickers: AMGN, CELG, CBST, GILD

    March Madness is well under way with the Final Four taking place this weekend. There is no doubt that the Final Four will be entertaining, but there is an even better type of madness going on called Biotech Madness! I have come up with my Final Four Biotech company selections as well as the winner, which will be announced later in this article.

    Biotech Facts and Opportunities

    • Biotechnology utilizes modern more »

  • Biotech Madness!

    By Greg Williamson - April 1, 2013 | Tickers: AMGN, CELG, CBST, GILD

    March Madness is well under way with the Final Four taking place this weekend. There is no doubt that the Final Four will be entertaining, but there is an even better type of madness going on called Biotech Madness! I have come up with my Final Four Biotech company selections as well as the winner, which will be announced later in this article.

    Biotech Facts and Opportunities

    • Biotechnology utilizes modern more »

  • The Danger of the One-Hit Wonder

    By Robert Hanley - March 27, 2013 | Tickers: AFFY, AMGN, VRX

    The drug development field is a potentially lucrative, although always dangerous area for small companies and their investors to participate in. The development process can take up to fifteen years from start to finish, at which point companies can look forward to managing post-approval activities and monitoring the drug manufacturing process. Even at the end, things can unfortunately go wrong. For a cautionary tale, let’s take the case of more »

  • Time-Tested Pharmaceutical Stocks

    By Shas Dey - March 26, 2013 | Tickers: AMGN, AZN, GSK

    This article looks at three dividend paying biotechnology and drug stocks - two with above 4% dividend yields, AstraZeneca (NYSE: AZN) and GlaxoSmithKline (NYSE: GSK), and one that apart from being a dividend stock also has a significant growth potential, Amgen (NASDAQ: AMGN).

    Rationale for Dividend Investing in Today's Economy

    Taxing bank deposits was indeed insanity, and one wonders why it was even considered. Fortunately, the Cyprus madness did not more »

  • Is DaVita Worth a Buy?

    By Anh HOANG - March 13, 2013 | Tickers: AMGN, DVA, FMS

    In order to be successful in investing, just pick a great company and stick with it through ups and downs. That is what Charlie Munger often advises investors to do. Indeed, Warren Buffett has become a better investor when his investment philosophy shifted towards great quality businesses. Recently, Berkshire Hathaway has been adding shares of DaVita Healthcare Partners (NYSE: DVA) to its portfolio, even as its share price reached its more »

  • Why Wouldn’t You Buy These Pharmaceutical Stocks?

    By Brian Gorban - March 4, 2013 | Tickers: AMGN, MRK, PFE

    Investors are always trying to find the right balance between risk andreward. I believe the following three pharmaceutical stocks below offer a nice balance: They are expected to show some nice growth, while also paying a healthy dividend that exceeds most other investment options.

    Is Pfizer (NYSE: PFE) right for you?            

    Dow component and pharmaceutical giant Pfizer is surely a juggernaut, with trailing-12-month revenue near $60 billion, and a market more »

  • Huge Upside Potential Despite Recent Rallies

    By Mohsin Saeed - February 19, 2013 | Tickers: AMGN, ONCY, PFE

    Shares of Oncolytics Biotech (NASDAQ: ONCY) have risen by more than 35% since last Thursday. This phenomenal rally started just after the company announced successful Phase III trial results for its primary drug candidate Reolysin. The company's stock has almost doubled in the last couple of months.

    This success of Reolysin shows that the company's stock has the ability to go even higher. Due to its cheap valuations more »

  • The Sum of Its Parts: Pharmaceuticals

    By Reuben Brewer - February 14, 2013 | Tickers: AMGN, JNJ, PFE

    Johnson & Johnson (NYSE: JNJ) is a massive and diversified healthcare focused company. While some competitors have been shedding businesses to focus on only one business segment, JNJ has long benefited from doing multiple things well. One of its two main growth engines is its pharmaceuticals business.

    Success is in the DNA

    Johnson & Johnson lives by a “credo” created by Robert Wood Johnson, a member of the company's founding family more »

  • A Pipeline Worth Buying

    By Mohsin Saeed - February 14, 2013 | Tickers: AMGN, PFE, TEVA

    The biotechnology industry is one of the most attractive industries for investors primarily due to its high returns. However, high returns also mean a higher risk due to frequent price fluctuations. In such a scenario Amgen (NASDAQ: AMGN) is the perfect stock because it is not only the biggest bio-pharmaceutical company in the world, but it also has strong drug sales that limit its downside. The company, however, is not more »

  • Four Analyst Calls on Monday Worth Noting

    By Brian Nichols - February 12, 2013 | Tickers: ALR, AMGN, ANGI, SCTY

    Sometimes an analyst issues a revised outlook or changes his/her rating, but does not inform investors of the reasons behind the call. These typically move stocks on the call alone; the price target and outlook. However, some analysts provide detailed reasons behind the call; these are the outlooks that should be noted and used as part of your fundamental research. Therefore, I am taking a look at such outlooks more »

  • Can Following The Insiders Into These Stocks Lead To Big Rewards?

    By Brian Gorban - February 11, 2013 | Tickers: AMGN, EMC, NLNK, VMW

    One strategy that has proven to be effective over time in determining whether a stock is moving higher is insider accumulation, due to one simple reason. Insiders sell shares for a variety of reason, but they buy them, just like us, because they believe the stock will move higher. Furthermore, they have an enviable vantage point of their company's day-to-day operations, and they may also have a large investment more »

  • HIV/AIDS and Gilead Sciences

    By Erik Dellith - February 11, 2013 | Tickers: AMGN, BMY, GILD, GSK, JNJ

    In honor of National Black HIV/AIDS Awareness Day, I focus on one of the biotech companies leading the charge against HIV/AIDS: Gilead Sciences (NASDAQ: GILD).  The company’s drugs help to lengthen the lives of many people living with HIV, while also providing sizeable revenue.  Further, the stock is currently attractively valued, and, with solid future growth prospects, is worth consideration by investors seeking exposure to the healthcare more »

  • Illogical Trends on Thursday Might Create Value ... or Value Traps

    By Brian Nichols - February 7, 2013 | Tickers: ALU, AMGN, CNW

    Earnings create movement and set the trend for a stock for the following three months. A stock can post a blowout quarter and see great movement and a shift from pessimism to optimism (i.e. Netflix) or vise versa. But sometimes, the market gets it wrong and the stock trends in an incorrect direction. Sometimes it creates value and other times it creates a value trap. With that being said more »

  • Serial Acquirers Can Be Good Investments

    By Reuben Brewer - February 7, 2013 | Tickers: AMGN, GOOG, IACI, JNJ, KMP

    Tech Crunch recently noted that 2,277 private technology companies were acquired in 2012 for almost $50 billion dollars. Those are big numbers. What's more interesting, however, is who is doing the buying. Google (NASDAQ: GOOG) and Facebook (FB) were highlighted as the most active buyers, which goes to show that innovative companies often bring in ideas and talent from the outside. Technology, though, isn't the only industry more »

  • Building A Better Drug Portfolio

    By Reuben Brewer - February 5, 2013 | Tickers: AMGN, JNJ, MRK, PFE

    It isn't difficult to find leaders in the pharmaceutical industry. There are two such companies in the Dow 30. It is much harder to find leaders in the biotechnology space. However, the one clear giant, Amgen (Nasdaq: AMGN), should probably be in every drug portfolio.

  • Page 1 of 4